Diagnostic Performance of [<sup>18</sup>F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer

Positron emission tomography using [<sup>18</sup>F]fluorodeoxyglucose (FDG PET) potentially underperforms for staging of patients with grade 1–2 estrogen receptor positive (ER+) breast cancer. The aim of this study was to retrospectively investigate the diagnostic accuracy of FDG PET in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ramsha Iqbal, Lemonitsa H. Mammatas, Tuba Aras, Wouter V. Vogel, Tim van de Brug, Daniela E. Oprea-Lager, Henk M. W. Verheul, Otto S. Hoekstra, Ronald Boellaard, Catharina W. Menke-van der Houven van Oordt
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	positron emission tomography (PET) [<sup>18</sup>F]FDG breast cancer estrogen receptor staging Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/d8c988063f0c45489f71114b436b3760
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d8c988063f0c45489f71114b436b3760
record_format	dspace
spelling	oai:doaj.org-article:d8c988063f0c45489f71114b436b37602021-11-25T17:20:12ZDiagnostic Performance of [<sup>18</sup>F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer10.3390/diagnostics111119542075-4418https://doaj.org/article/d8c988063f0c45489f71114b436b37602021-10-01T00:00:00Zhttps://www.mdpi.com/2075-4418/11/11/1954https://doaj.org/toc/2075-4418Positron emission tomography using [<sup>18</sup>F]fluorodeoxyglucose (FDG PET) potentially underperforms for staging of patients with grade 1–2 estrogen receptor positive (ER+) breast cancer. The aim of this study was to retrospectively investigate the diagnostic accuracy of FDG PET in this patient population. Suspect tumor lesions detected on conventional imaging and FDG PET were confirmed with pathology or follow up. PET-positive lesions were (semi)quantified with standardized uptake values (SUV) and these were correlated with various pathological features, including the histological subtype. Pre-operative imaging detected 155 pathologically verified lesions (in 74 patients). A total of 115/155 (74.2%) lesions identified on FDG PET were classified as true positive, i.e., malignant (in 67 patients) and 17/155 (10.8%) lesions as false positive, i.e., benign (in 9 patients); 7/155 (4.5%) as false negative (in 7 patients) and 16/155 (10.3%) as true negative (in 14 patients). FDG PET incorrectly staged 16/70 (22.9%) patients. The FDG uptake correlated with histological subtype, showing higher uptake in ductal carcinoma, compared to lobular carcinoma (<i>p</i> < 0.05). Conclusion: Within this study, FDG PET inadequately staged 22.9% of grade 1–2, ER + BC cases. Incorrect staging can lead to inappropriate treatment choices, potentially affecting survival and quality of life. Prospective studies investigating novel radiotracers are urgently needed.Ramsha IqbalLemonitsa H. MammatasTuba ArasWouter V. VogelTim van de BrugDaniela E. Oprea-LagerHenk M. W. VerheulOtto S. HoekstraRonald BoellaardCatharina W. Menke-van der Houven van OordtMDPI AGarticlepositron emission tomography (PET)[<sup>18</sup>F]FDGbreast cancerestrogen receptorstagingMedicine (General)R5-920ENDiagnostics, Vol 11, Iss 1954, p 1954 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	positron emission tomography (PET) [<sup>18</sup>F]FDG breast cancer estrogen receptor staging Medicine (General) R5-920
spellingShingle	positron emission tomography (PET) [<sup>18</sup>F]FDG breast cancer estrogen receptor staging Medicine (General) R5-920 Ramsha Iqbal Lemonitsa H. Mammatas Tuba Aras Wouter V. Vogel Tim van de Brug Daniela E. Oprea-Lager Henk M. W. Verheul Otto S. Hoekstra Ronald Boellaard Catharina W. Menke-van der Houven van Oordt Diagnostic Performance of [<sup>18</sup>F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer
description	Positron emission tomography using [<sup>18</sup>F]fluorodeoxyglucose (FDG PET) potentially underperforms for staging of patients with grade 1–2 estrogen receptor positive (ER+) breast cancer. The aim of this study was to retrospectively investigate the diagnostic accuracy of FDG PET in this patient population. Suspect tumor lesions detected on conventional imaging and FDG PET were confirmed with pathology or follow up. PET-positive lesions were (semi)quantified with standardized uptake values (SUV) and these were correlated with various pathological features, including the histological subtype. Pre-operative imaging detected 155 pathologically verified lesions (in 74 patients). A total of 115/155 (74.2%) lesions identified on FDG PET were classified as true positive, i.e., malignant (in 67 patients) and 17/155 (10.8%) lesions as false positive, i.e., benign (in 9 patients); 7/155 (4.5%) as false negative (in 7 patients) and 16/155 (10.3%) as true negative (in 14 patients). FDG PET incorrectly staged 16/70 (22.9%) patients. The FDG uptake correlated with histological subtype, showing higher uptake in ductal carcinoma, compared to lobular carcinoma (<i>p</i> < 0.05). Conclusion: Within this study, FDG PET inadequately staged 22.9% of grade 1–2, ER + BC cases. Incorrect staging can lead to inappropriate treatment choices, potentially affecting survival and quality of life. Prospective studies investigating novel radiotracers are urgently needed.
format	article
author	Ramsha Iqbal Lemonitsa H. Mammatas Tuba Aras Wouter V. Vogel Tim van de Brug Daniela E. Oprea-Lager Henk M. W. Verheul Otto S. Hoekstra Ronald Boellaard Catharina W. Menke-van der Houven van Oordt
author_facet	Ramsha Iqbal Lemonitsa H. Mammatas Tuba Aras Wouter V. Vogel Tim van de Brug Daniela E. Oprea-Lager Henk M. W. Verheul Otto S. Hoekstra Ronald Boellaard Catharina W. Menke-van der Houven van Oordt
author_sort	Ramsha Iqbal
title	Diagnostic Performance of [<sup>18</sup>F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer
title_short	Diagnostic Performance of [<sup>18</sup>F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer
title_full	Diagnostic Performance of [<sup>18</sup>F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer
title_fullStr	Diagnostic Performance of [<sup>18</sup>F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer
title_full_unstemmed	Diagnostic Performance of [<sup>18</sup>F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer
title_sort	diagnostic performance of [<sup>18</sup>f]fdg pet in staging grade 1–2, estrogen receptor positive breast cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/d8c988063f0c45489f71114b436b3760
work_keys_str_mv	AT ramshaiqbal diagnosticperformanceofsup18supffdgpetinstaginggrade12estrogenreceptorpositivebreastcancer AT lemonitsahmammatas diagnosticperformanceofsup18supffdgpetinstaginggrade12estrogenreceptorpositivebreastcancer AT tubaaras diagnosticperformanceofsup18supffdgpetinstaginggrade12estrogenreceptorpositivebreastcancer AT woutervvogel diagnosticperformanceofsup18supffdgpetinstaginggrade12estrogenreceptorpositivebreastcancer AT timvandebrug diagnosticperformanceofsup18supffdgpetinstaginggrade12estrogenreceptorpositivebreastcancer AT danielaeoprealager diagnosticperformanceofsup18supffdgpetinstaginggrade12estrogenreceptorpositivebreastcancer AT henkmwverheul diagnosticperformanceofsup18supffdgpetinstaginggrade12estrogenreceptorpositivebreastcancer AT ottoshoekstra diagnosticperformanceofsup18supffdgpetinstaginggrade12estrogenreceptorpositivebreastcancer AT ronaldboellaard diagnosticperformanceofsup18supffdgpetinstaginggrade12estrogenreceptorpositivebreastcancer AT catharinawmenkevanderhouvenvanoordt diagnosticperformanceofsup18supffdgpetinstaginggrade12estrogenreceptorpositivebreastcancer
_version_	1718412498696142848

Diagnostic Performance of [<sup>18</sup>F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer

Ejemplares similares